The global market for regenerative medicines raised $4.8bn in the first half of 2019; a slowdown compared to the same period of 2018, though the sector is poised for additional growth, says ARM CEO.
Regenerative medicine raised $13.3bn in funds during 2018 but investors question whether treatments can be manufactured consistently, according to AMR annual report.
Cryoport is supporting a record number of clinical trials driven by rapid growth in regenerative medicine – a space that will continue to grow and outpace the pharmaceutical industry, says CCO.
Japan’s early approval process for cell and gene therapies still suffers from clinical recruitment challenges and a solid manufacturing framework, says regenerative medicine group FIRM.
Cell therapy firms must invest in engineering and learn from biopharma according to the US Government, which says high cost of regenerative treatments is slowing uptake.
Fujifilm will buy Cellular Dynamics International (CDI) for $307m to add induced stem cells to its offering and further build in regenerative medicines.